Serological responses to mycoplasmas in HIV-infected and non-infected individuals. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Serological responses to mycoplasmas in HIV-infected and non-infected individuals.

AIDS. 1992 Nov;6(11):1287-92. Unique Identifier : AIDSLINE MED/93112300
Hakkarainen K; Jansson E; Ranki A; Valle SL; Krohn KJ; Institute of Biomedical Sciences, University of Tampere, Finland.

Abstract: OBJECTIVE: To assess the frequency of mycoplasma infections in HIV-antibody-positive and -negative individuals by studying the serological responses against mycoplasmas, especially Mycoplasma fermentans and M. pirum. DESIGN: An enzyme-linked immunosorbent assay (ELISA) was used to measure immunoglobulin G (IgG) class antibody concentrations against six mycoplasma species in sera of HIV-positive and HIV-negative individuals. METHODS: Serum samples were obtained from 30 HIV-positive individuals (10 asymptomatics, 10 with lymphadenopathy syndrome and 10 with AIDS), 10 HIV-negative partners of HIV-positive individuals and 40 HIV-negative blood donors. Antibodies to M. fermentans strains incognitus and PG18, M. pirum, M. genitalium, M. pneumoniae and M. hominis were assessed by immunoblot or ELISA. Absorbance values were taken as a semiquantitative measurement for antibody concentration and an arbitrary cut-off value (0.8) was set to establish seroprevalence. RESULTS: There was no significant difference in the mean IgG concentrations of any of the six mycoplasmas between HIV-positive and HIV-negative groups. Antibody concentrations were also similar in different clinical phases of HIV infection. Antibody concentrations to different mycoplasma strains were compared with each other to reveal eventual cross-reactions caused by shared antigens; the strongest correlation (r = 0.836) was found between M. fermentans strains incognitus and M. pirum antibody concentrations. The correlation between M. fermentans strains incognitus and PG18 was also significant but weaker (r = 0.522). No shared antigens between M. fermentans strain incognitus and M. pirum were demonstrated by immunoblot. CONCLUSIONS: Antibodies against M. fermentans type strain PG18, strain incognitus and against M. pirum are detected infrequently and their presence does not correlate with HIV infection per se or with the clinical stage of HIV infection.
Keywords: Antibodies, Bacterial/*BLOOD Cohort Studies Female Finland/EPIDEMIOLOGY Human HIV Infections/EPIDEMIOLOGY/ETIOLOGY/*MICROBIOLOGY HIV Seropositivity/MICROBIOLOGY IgG/BLOOD Male Mycoplasma/*IMMUNOLOGY/PATHOGENICITY Mycoplasma Infections/COMPLICATIONS/EPIDEMIOLOGY/IMMUNOLOGY Seroepidemiologic Methods Support, Non-U.S. Gov't JOURNAL ARTICLEKWDantibodies,bacterial/KWDbloodcohortstudiesfemalefinland/epidemiologyhumanhivinfections/epidemiology/etiology/KWDmicrobiologyhivseropositivity/microbiologyigg/bloodmalemycoplasma/KWDimmunology/pathogenicitymycoplasmainfections/complications/epidemiology/immunologyseroepidemiologicmethodssupport,non-uKWDsKWDgov'tjournalarticle
930430
M9340803

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .